Tazemetostat hydrobromide
Modify Date: 2024-01-09 17:57:10
Tazemetostat hydrobromide structure
|
Common Name | Tazemetostat hydrobromide | ||
|---|---|---|---|---|
| CAS Number | 1467052-75-0 | Molecular Weight | 653.65 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C34H45BrN4O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Tazemetostat hydrobromideTazemetostat hydrobromide (EPZ-6438 hydrobromide) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat hydrobromide inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat hydrobromide inhibits Rat EZH2 with an IC50 of 4 nM. Tazemetostat hydrobromide also inhibits EZH1 with an IC50 of 392 nM. |
| Name | Tazemetostat hydrobromide |
|---|
| Description | Tazemetostat hydrobromide (EPZ-6438 hydrobromide) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat hydrobromide inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat hydrobromide inhibits Rat EZH2 with an IC50 of 4 nM. Tazemetostat hydrobromide also inhibits EZH1 with an IC50 of 392 nM. |
|---|---|
| Related Catalog | |
| Target |
EZH2 WT:2.5 nM (Ki) EZH2:11 nM (IC50, in peptide assay) EZH2:16 nM (IC50, in nucleosome assay) Rat EZH2:4 nM (IC50) EZH1:392 nM (IC50) |
| References |
| Molecular Formula | C34H45BrN4O4 |
|---|---|
| Molecular Weight | 653.65 |